Agios Pharmaceuticals Inc. published efficacy and safety data from the ongoing phase I/II dose-escalation and expansion study evaluating investigational oral Idhifa (enasidenib) in patients with relapsed or refractory acute myeloid leukemia and an isocitrate dehydrogenase-2 mutation.
FDA approved the supplemental Biologics License Application for Vectibix (panitumumab) for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.
A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
The class of immunotherapies known as checkpoint inhibitors have proven to be a highly effective and advantageous treatment option for many cancer patients. But, oncologists have no reliable way to determine in advance which patients are likely to respond to these drugs.
According to a new study from Fred Hutchinson Cancer Research Center, 53 percent of cancer patients' emergency department visits could be avoided with better symptom management and greater availability of outpatient care tailored to their needs.
University of California San Diego School of Medicine researchers report lesions of the appendix are being over diagnosed as invasive cancer.
Oncoceutics Inc. announced results from the first cohort of its phase II trial for patients with recurrent glioblastoma, which showed median overall survival in the first cohort of 17 patients two times that indicated in the current GBM patient literature.
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic cancer, according to a study at MD Anderson Cancer Center.
A study at MD Anderson Cancer Center revealed new details about how enzyme acetyl-CoA synthetase 2 allows brain tumors to grow despite their harsh surroundings.
Martin Edelman, chair of hematology and oncology at Fox Chase Cancer Center, presented the results of a clinical study testing palbociclib, a drug used to treat breast cancer, in patients with squamous non-small cell lung cancer at the American Society of Clinical Oncology.
